Insider · CIK 0001743658
Dawn Halkuff
Files at XERS (Xeris Biopharma Holdings, Inc.). First filing Nov 21, 2023, latest Jun 5, 2026.
In brief
Dawn Halkuff files SEC Form 4 as director at XERS (Xeris Biopharma Holdings, Inc.). Since Nov 21, 2023, Dawn Halkuff has reported 1 open-market buy worth $9,954 and 2 open-market sells worth $431k, the latest filed on Jun 5, 2026.
A track record needs three past buys with six months of prices behind them; Dawn Halkuff has 0, so none is measured yet.
The newest scored trade: sold $122k of XERS on Jun 4, 2026, filed Jun 5, 2026, scored 25 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $122k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XERS: Xeris Biopharma Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Xeris Biopharma Holdings, Inc. | $122k 20,000 shares | -17% | +41% from low-38% from high | |
| 47Moderate | Xeris Biopharma Holdings, Inc. | $309k 42,500 shares | -27% | +164% from low0% from high | |
| 46Moderate | Xeris Biopharma Holdings, Inc. | $9,954 5,410 shares | - | +77% from low-39% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 4, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 20,000 0.01% of outstanding | $118k | Jun 4, 2026 | none |
| Aug 12, 2025 | XERS XERIS PHARMACEUTICALS, INC. | 42,500 0.03% of outstanding | $309k | Aug 12, 2025 | none |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $6.09 | $122k | 95,000 | Jun 5, 2026 |
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock10b5-1 | +24,193 | $0.00 | $0 | 119,193 | Jun 5, 2026 |
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Aug 12, 2025 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock | -42,500 | $7.28 | $309k | 115,000 | Aug 13, 2025 |
| Jun 4, 2025 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 157,500 | Jun 4, 2025 |
| Nov 20, 2023 | XERS Xeris Biopharma Holdings, Inc. | POpen-market purchase Common Stockindirect: By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017 | +5,410 | $1.84 | $9,954 | 5,410 | Nov 21, 2023 |
Questions about Dawn Halkuff
Answered from the filings on this page, as of the latest one.
Is Dawn Halkuff buying or selling?
In the last 12 months Dawn Halkuff reported 0 open-market buys worth $0 and 1 open-market sell worth $122k on SEC Form 4; the latest was sold $122k of XERS on Jun 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Dawn Halkuff's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dawn Halkuff has 0.
Where does Dawn Halkuff file Form 4?
Dawn Halkuff has filed Form 4 at XERS (Xeris Biopharma Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.